Paxalisib + Opdualag + Irinotecan (drug) + Temozolomide (TMZ)
Phase 1/2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Childhood Cancer
Conditions
Childhood Cancer, Childhood Solid Tumor, Childhood Brain Tumor, Recurrent Cancer, Refractory Cancer
Trial Timeline
Jul 10, 2024 → Dec 1, 2035
NCT ID
NCT06208657About Paxalisib + Opdualag + Irinotecan (drug) + Temozolomide (TMZ)
Paxalisib + Opdualag + Irinotecan (drug) + Temozolomide (TMZ) is a phase 1/2 stage product being developed by Bristol Myers Squibb for Childhood Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06208657. Target conditions include Childhood Cancer, Childhood Solid Tumor, Childhood Brain Tumor.
What happened to similar drugs?
1 of 5 similar drugs in Childhood Cancer were approved
Approved (1) Terminated (0) Active (4)
Hype Score Breakdown
Clinical
9
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06208657 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in Childhood Cancer